Skyepharma, a french pharmaceutical service provider (CDMO) with over 25 years of expertise in complex solid forms. Its range of services covers all kinds of needs for pharmaceutical product development from R&D to manufacturing and packaging for international markets. This year, Skyepharma is launching a new segregated and contained FDA & GMP area dedicated to HPAPI products, including OEB4/5 molecules, NCEs, and immuno and oncology drugs. This area will provide clients with a wide range of services such as R&D, clinical supply, and small to mid-size commercial production (up to 70 kg batch size). Skyepharma has a strong reputation in development and manufacturing of solid dosage forms like tablets and capsules. Its agility and expertise, particularly in handling highly potent APIs and controlled release techniques, position Skyepharma as a leader in the field of innovation, benefiting its clients and partners.